Your Product Is Ready. Your Launch Strategy Isn’t

Published 10 August 2026

Author(s): Komal Gurnani, ZS

Insights into the "differentiation paradox" from a study of 340 drug launches.

Why do superior pharma products lose the last mile of adoption to "good enough" competitors? The conventional explanation: gaps in messaging, access, or execution. A study of 340 pharma launches across 12 categories tells a different story. Even products with a competitive advantage underperform three-year consensus targets 29% of the time; product superiority alone correlates with 49% overperformance. But when product strength is paired with organizational commitment architecture—the institutional infrastructure that resolves friction between a customer’s decision to adopt and the moment they experience value—overperformance rises to 67%.

The multiplier is not the product. It is the system around it.